-
Mashup Score: 14
Age-based recommendations for adult pneumococcal vaccination lowered from 65 to 50 years of age and older National-level CDC surveillance data shows CAPVAXIVE covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases, compared to approximately 52% covered by PCV20 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to update the adult age-based pneumococcal vaccination guidelines and recommends CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for pneumococcal vaccination in adults 50 years of age and older. The updated ACIP guidelines recommend a single dose of CAPVAXIVE for: Adults 50 years of age and older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown; Adults 19-49 years of age with certain underlying medical
Source: www.merck.comCategories: General Medicine News, PayerTweet
Today, the CDC’s Advisory Committee on Immunization Practices (#ACIP) voted to update the adult pneumococcal vaccination recommendations, expanding access to those at risk of #pneumococcal disease. Learn more: https://t.co/LWreJD6E1a https://t.co/M8aun8KF1S